Review of Ophthalmology February 2012 : covtip 2
Important Safety Information (continued) Warnings and Precautions (continued) Adverse Reactions: The most common (25%-45%) adverse event with LUMIGAN ® was conjunctival hyperemia. Approximately 0.5% to 3% of patients discontinued therapy due to conjunctival hyperemia. Other common events (> 10%) included growth of eyelashes and ocular pruritus. Please see brief Prescribing Information on page 5 inside this journal. , a trademark of MMIT, as of January 2012. 1. Formulary Compass Database ™ ©2012 Allergan, Inc., Irvine, CA 92612 ® marks owned by Allergan, Inc. Formulary Compass Database is a trademark owned by Managed Markets Insight & Technology, LLC. Travatan Z is a registered trademark owned by Novartis AG. www.lumigan.com APC66BQ12 120356
Publication List
Using a screen reader? Click Here